Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO Comments On Follow-On Biologics Will Include Manufacturing Anecdotes

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA officials' questions to industry reps during public workshop focus on the level of studies that should be required for follow-on biologic applications, particularly in comparison to requirements for manufacturing process changes by innovators.

You may also be interested in...



FDA Follow-on Proteins Draft Guidance Will Be Followed By Third Public Meeting

The agency's next step on "generic" biologics is to release a background document on FDA's past regulatory and scientific treatment of protein products. The draft guidance – which could be a set of "interlocking" guidances – will be released subsequent to the background document.

FDA Follow-on Proteins Draft Guidance Will Be Followed By Third Public Meeting

The agency's next step on "generic" biologics is to release a background document on FDA's past regulatory and scientific treatment of protein products. The draft guidance – which could be a set of "interlocking" guidances – will be released subsequent to the background document.

GPhA Asks FDA To Create Task Force On Generic Biopharmaceuticals

The agency should abandon its “arbitrator” role in the face of the brand industry’s continued reluctance to discuss a path forward, GPhA maintains. FDA should put together an analysis of the issues to be presented at an upcoming FDA/DIA meeting.

Related Content

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel